Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve

Guimarães, Helio P., Lopes, Renato D., de Barros e Silva, Pedro G.M., Liporace, Idelzuita L., Sampaio, Roney O., Tarasoutchi, Flávio, Hoffmann-Filho, Conrado R., de Lemos Soares Patriota, Rodrigo, Leiria, Tiago L.L., Lamprea, Diana, Precoma, Dalton B., Atik, Fernando A., Silveira, Fabio S., Farias, Fabio R., Barreto, Diogo O., Almeida, Adail P., Zilli, Alexandre C., de Souza Neto, João D., Cavalcante, Margaret A., Figueira, Fernando A.M.S., Kojima, Flávia C.S., Damiani, Lucas, Santos, Renato H.N., Valeis, Nanci, Campos, Viviane B., Saraiva, Jose F.K., Fonseca, Francisco H., Pinto, Ibraim M., Magalhães, Carlos C., Ferreira, Joao F.M., Alexander, John H., Pavanello, Ricardo, Cavalcanti, Alexandre B., Berwanger, Otavio·2020·New England Journal of Medicine

Abstract

BACKGROUND: The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. METHODS: In this randomized trial, we compared rivaroxaban (20 mg once daily) with dose-adjusted warfarin (target international normalized ratio, 2.0 to 3.0) in patients with atrial fibrillation and a bioprosthetic mitral valve. The primary outcome was a composite of death, major cardiovascular events (stroke, transient ischemic attack, systemic embolism, valve thrombosis, or hospitalization for heart failure), or major bleeding at 12 months. RESULTS: A total of 1005 patients were enrolled at 49 sites in Brazil. A primary-outcome event occurred at a mean of 347.5 days in the rivaroxaban group and 340.1 days in the warfarin group (difference calculated as restricted mean survival time, 7.4 days; 95% confidence interval [CI], -1.4 to 16.3; P<0.001 for noninferiority). Death from cardiovascular causes or thromboembolic events occurred in 17 patients (3.4%) in the rivaroxaban group and in 26 (5.1%) in the warfarin group (hazard ratio, 0.65; 95% CI, 0.35 to 1.20). The incidence of stroke was 0.6% in the rivaroxaban group and 2.4% in the warfarin group (hazard ratio, 0.25; 95% CI, 0.07 to 0.88). Major bleeding occurred in 7 patients (1.4%) in the rivaroxaban group and in 13 (2.6%) in the warfarin group (hazard ratio, 0.54; 95% CI, 0.21 to 1.35). The frequency of other serious adverse events was similar in the two groups. CONCLUSIONS: In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. (Funded by PROADI-SUS and Bayer; RIVER ClinicalTrials.gov number, NCT02303795.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2029603

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 289

Metadata

Authors
Guimarães, H. P., Lopes, R. D., de Barros e Silva, P. G. M., Liporace, I. L., Sampaio, R. O., Tarasoutchi, F., Hoffmann-Filho, C. R., de Lemos Soares Patriota, R., Leiria, T. L. L., Lamprea, D., Precoma, D. B., Atik, F. A., Silveira, F. S., Farias, F. R., Barreto, D. O., Almeida, A. P., Zilli, A. C., de Souza Neto, J. D., Cavalcante, M. A., Figueira, F. A. M. S., Kojima, F. C. S., Damiani, L., Santos, R. H. N., Valeis, N., Campos, V. B., Saraiva, J. F. K., Fonseca, F. H., Pinto, I. M., Magalhães, C. C., Ferreira, J. F. M., Alexander, J. H., Pavanello, R., Cavalcanti, A. B., & Berwanger, O.
Venue
New England Journal of Medicine
Published
2020-11-26
Volume
383
Issue
22
Pages
2117-2126
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3098781229
Cited by
289
References
25
FWCI
24.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. https://app.cochat.ai/papers/10.1056/nejmoa2029603
The paper
Guimarães, H. P., Lopes, R. D., de Barros e Silva, P. G. M., Liporace, I. L., Sampaio, R. O., Tarasoutchi, F., Hoffmann-Filho, C. R., de Lemos Soares Patriota, R., Leiria, T. L. L., Lamprea, D., Precoma, D. B., Atik, F. A., Silveira, F. S., Farias, F. R., Barreto, D. O., Almeida, A. P., Zilli, A. C., de Souza Neto, J. D., Cavalcante, M. A., . . . Berwanger, O. (2020). Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2029603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.